Gastric bypass surgery (GBP) results in important and sustained weight loss and remarkable improvement of Type 2 diabetes. The favorable change in the incretin gut hormones is thought to be responsible, in part, for diabetes remission after GBP, independent of weight loss. However, the relative role of the change in incretins and of weight loss is difficult to differentiate. After GBP, the plasma concentrations of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucosedependent insulinotropic polypeptide increase postprandially by three-to fivefold. The postprandial incretin effect on insulin secretion, blunted in diabetes, improves rapidly after the surgery. In addition to the change in incretins, the pattern of insulin secretion in response to oral glucose changes after GBP, with recovery of the early phase and significant decrease in postprandial glucose levels. These changes were not seen after an equivalent weight loss by diet. The improved insulin release and glucose tolerance after GBP were shown by others to be blocked by the administration of a GLP-1 antagonist, demonstrating that the favorable metabolic changes after GBP are, in part, GLP-1 dependent. The improved incretin levels and effect persist years after GBP, but their long-term effect on glucose metabolism, and on hypoglycemia post GBP are yet unknown. Understanding the mechanisms by which incretin release is exaggerated postprandially after GBP may help develop new less invasive treatment options for obesity and diabetes. Changes in rate of eating, gastric emptying, intestinal transit time, nutrient absorption and sensing, as well as bile acid metabolism, may all be implicated.
Bariatric surgery, the only efficient long-term weight loss treatment for morbid obesity, is a uniquely suited model to investigate the role of gut hormones in weight loss and diabetes remission.
One of the major benefits of surgical weight loss is the improvement or resolution of Type 2 diabetes (T2DM) in 50-80% of cases. 1, 2 The rapidity of the onset and the magnitude of the effect of gastric bypass (GBP) surgery on diabetes remain largely unexplained. Some determinants of impaired insulin secretion in T2DM, such as glucose or lipid toxicity, 3, 4 likely improve as a result of weight loss. In contrast, the change of the gut hormone incretins after GBP, 5, 6 and their resulting effect on insulin or on glucagon secretion, could be the mediator of the greater improvement of glucose levels after GBP 5, 6 as compared with diet or gastric banding.
What are the incretins?
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are gastrointestinal hormones secreted from the duodenal K cells and ileal L cells, respectively. [7] [8] [9] Together, the two incretins are responsible for B50% of postprandial insulin secretion. [10] [11] [12] The incretin effect is described as the differential insulin response after oral glucose compared with an equivalent dose of intravenous glucose. 11 In addition to its insulinotropic effect, GLP-1 delays gastric emptying, 13 decreases appetite and promotes weight loss, 13, 14 inhibits glucagon 15 and may improve insulin sensitivity. 16 GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase 4. The incretin effect on insulin secretion is impaired in patients with T2DM. 17 GLP-1 analog and dipeptidyl peptidase 4 inhibitors are currently used as anti-diabetic agents.
18
Change of incretins after bypass surgeries for weight loss
Reports of increased incretin levels after bypass surgeries started in the late 1970s/early 1980s, at a time when no commercial assays were available. GLP-1 consistently increased after jejunoileal bypass, biliopancreatic diversion or GBP. [19] [20] [21] More recent reports confirm a significant increase of GLP-1 levels by a factor 5-10 after GBP, in response to a meal 22 or to oral glucose. 5 The effect of bypass surgeries on changes in GIP levels are less consistent with either elevated or decreased levels. 19, 21, [23] [24] [25] We reported an increase of GIP levels 1 month after GBP in morbidly obese patients with T2DM. 5 In addition to the postprandial increase of circulating incretins concentration, we have shown that the incretin effect on insulin secretion, blunted in patients with diabetes, normalized to the levels of nondiabetic controls as early as 1 month after GBP surgery.
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These patients, who had diagnosed diabetes for less than 5 years, were well controlled (mean hemoglobin A1C, 6%) and on minimum oral therapy. Recent data in the Goto-Kakizaki rats show that improved glucose tolerance after duodenojejunal bypass is reversed by the administration of the GLP-1 receptor antagonist exendin 9-39. This elegant proof-ofconcept study provides direct evidence that improvement of glucose tolerance following a GBP-like surgery is mediated, at least in part, by enhanced GLP-1 action. 26 
Effect of weight loss versus bypass on incretins
Previous data suggested that a diet-induced weight loss (À18.8 kg) increased GLP-1 levels in response to a test meal. 27 To address the question of the possible role of weight loss on the change in incretin levels and effect after GBP surgery, we designed a prospective study with a surgical group studied before and 1 month after GBP and a matched diet group studied before and after a diet-induced equivalent weight loss. Our working hypothesis was that the increase in incretin levels and incretin effect would be greater after GBP surgery than after equivalent weight loss by diet. The inclusion criteria for the surgical group and the diet group were identical: morbidly obese patients with body mass index435 kg m
À2
, with T2DM of o5 years duration, not on insulin, thiazolidinedione, exenatide or dipeptidyl peptidase 4 inhibitor, with hemoglobin A1Co8%, ageo60 years, of all ethnic background. The GBP group was studied first. Participants in the diet group were recruited afterward, fit the same inclusion criteria and were matched for body weight, body mass index, age, diabetes control and duration with patients from the surgical group. The diet consisted of meal replacement, 1000-1200 kcal per day, given on weekly outpatient visits. The duration of weight loss was not set but the expectation was that the participants would lose 10 kg of weight in 4-8 weeks. The patients were maintained on negative energy balance while retested after diet weight loss. Diabetes management during diet included self-glucose monitoring by the patients and the adjustment of medications to avoid hypoglycemia. At baseline and after weight loss, patients were studied off diabetes medications for 72 h. The results of these experiments have been published elsewhere. 6 In brief, patients in the GBP and diet groups lost the same amount of weight (B10 kg). Diabetes medications were discontinued at the time of surgery for all GBP patients, and were decreased or stopped for diet patients, using an algorithm based on standard criteria of target glucose control. There was a significant and similar decrease of fasting glucose and fasting insulin after diet and after GBP. Recovery of the early-phase insulin secretion in response to oral glucose and the improvement in incretin levels and effect were, however, observed only after GBP and not after diet. Recent clinical studies of various types of bypass surgeries and/or ileal transposition in humans with body mass index o35 kg m À2 suggest that diabetes can be improved without weight loss. 28 Data on gut hormones in these patients have not been provided.
Long-term changes of incretins
Data suggest that the changes observed early after GBP persist over time. Cross-sectional data from Naslund et al.
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show persistent elevated postprandial GLP-1 and GIP levels 20 years after duodenal-jejunal bypass compared with obese non-operated controls. Our own data show persistently increased GLP-1 response to oral glucose and GIP up to 3 years after GBP in patients with diabetes remission and normal incretin effect. With GBP weight loss, some parameters, such as fasting glucose, fasting insulin, leptin or adiponectin, improve as a function of weight loss in the first year. 30 Other parameters, such as incretin levels and effect, early-phase insulin release during the oral glucose tolerance test, and the insulinogenic index all improve rapidly 1 month after GBP without further change at 6 and 12 months, in spite of continuous weight loss. This suggests that some changes occur as a result of the surgery, independent of weight loss, whereas other changes are clearly weight-loss related. It remains unknown whether the improved postprandial insulin and glucose levels observed 1 month after GBP are responsible for the later development of hyperinsulinemic hypoglycemia with 31 or without 32 nesidioblastosis.
Although GLP-1 has been shown to preserve human islet in vitro 33 and prevent b-cell apoptosis in rodents, 34 there are no human data to suggest that GLP-1 increases b-cell mass after bypass in humans. An elegant study by McLaughin et al. 35 demonstrated that hyperinsulinemic hypoglycemia post GBP is not due to the dysfunction of the b cell, but
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rather due to the accelerated mode of nutrient delivery to the lower intestine. Administering the same meal PO via the alimentary limb, generated rapid release of GLP-1 and insulin resulting in hypoglycemia. Administering the same meal via a gastrostomy in the bypassed gastric remnant connected to the duodenal limb did not trigger this exaggerated insulin response and hypoglycemia. 35 Mechanisms of incretin release after GBP: foregut and hindgut hypotheses
As a result of GBP, a small gastric pouch of about 30 cc is anastomosed directly to the distal part of the jejunum (alimentary limb). The rest of the stomach, including the pylorus, duodenum and part of the jejunum is shunted from nutrients (biliopancreatic limb) and reattached to the ileum to allow gastrointestinal and pancreatic juice to be mixed with nutrients in the distal intestine (common limb). Studies in the Goto-Kakizaki rat suggest that the exclusion of the upper gut (foregut hypothesis), rather than weight loss, benefits glucose tolerance. 36, 37 Rats after gastrojejunal bypass have better glucose tolerance than sham-operated pair-fed control animals with equivalent body weight, or rats with gastrojejunal anastomosis. 36 The hindgut hypothesis suggests that the rapid stimulation of the distal ileum by nutrients is responsible for increased GLP-1 and beneficial effect on glucose tolerance, similar to data obtained with ileal transposition in rodents. 38, 39 There are few data in humans to support these hypotheses. After GBP, the emptying of the gastric pouch is faster for liquids but delayed for solids. 22, 40 Accelerated gastric emptying and intestinal transit time for liquid 22 may result in rapid release of GLP-1 by the distal ileum, which is rapidly put in contact with nutrients. It is likely that both duodenal exclusion (foregut hypothesis) and the rapid exposure of the distal ileum to undigested nutrients (hindgut hypothesis) 38, 39 are possible mechanisms that may contribute to elevated incretin levels after GBP; however, this has not yet been carefully studied in humans. The duodenal exclusion hypothesis is, to a degree, proven invalid by the results of vertical sleeve gastrectomy, which results in diabetes remission in a large percentage of patients and an increase in gut hormones, very similar to GBP, in spite of a functional duodenum. 41 
Other hormones
The incretins are not the only factors contributing to diabetes improvement after GBP surgery. We have shown that adiponectin increases and leptin decreases with weight loss after GBP, whereas abnormally elevated proinsulin and amylin decrease, as b-cell function improves, in patients with diabetes after GBP. 30 In parallel to GLP-1,
PYY3À36
(ref. 42) and oxyntomodulin, 43 also released by the L cells, increased postprandially after GBP but not after diet.
The changes of ghrelin after GBP are more complex than initially described. 44 We have recently shown that although circulating ghrelin concentration decreased initially after GBP, it increased in proportion to weight loss 1 year after this surgery. 45 
Conclusion
The magnitude of weight loss (B40%) and its persistence (years) are considered as the major contributors to glucose control after GBP. However, the data clearly show that secondary to the bypass procedure, beneficial changes of incretin levels and effect occur rapidly after GBP, resulting in an improved insulin secretion profile and decreased postprandial glucose. Understanding the mechanisms of diabetes remission after GBP surgery should help understand the role of the gut in the physiopathology of T2DM, and help discover new therapeutic surgical or medical intervention. 
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